Sana Biotechnology to present first-in-human hypoimmune islet transplant data at EASD 2026
PUBT · 3d ago
Share
Listen to the news
- Sana Biotechnology disclosed first-in-human clinical data from an investigator-sponsored transplant of UP421 hypoimmune allogeneic primary islet cells in type 1 diabetes.
- The transplant was performed without any immunosuppression, highlighting the company’s HIP immune-evasion engineering approach.
- The data are scheduled for presentation at an EASD 2026 symposium in Milan on Oct. 2, 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sana Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607010900PRIMZONEFULLFEED9754558) on July 01, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved